Cargando…

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report

ALK-EML4 fusion-positive lung adenocarcinomas (LUADs) are effectively treated with ALK tyrosine kinase inhibitors, but most patients eventually develop resistance to these drugs owing to ALK-dependent or independent mechanisms. Endothelial to mesenchymal transformation with SCLC development is an AL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majeed, Umair, Li, Shenduo, Seegobin, Karan, Nassar, Aziza, Manochakian, Rami, Zhao, Yujie, Lou, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345357/ https://www.ncbi.nlm.nih.gov/pubmed/37456921 http://dx.doi.org/10.1016/j.jtocrr.2023.100536

Ejemplares similares

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
por: Ye, Zhifeng, et al.
Publicado: (2023)

Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report
por: Hu, Jia, et al.
Publicado: (2020)

Lorlatinib for ALK‐fused, infant‐type hemispheric glioma with lung metastasis: a case report
por: Lai, Mingyao, et al.
Publicado: (2023)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

EML4-ALK fusion gene in non-small cell lung cancer
por: Lei, Yu, et al.
Publicado: (2022)

Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
por: Seegobin, Karan, et al.
Publicado: (2020)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

A novel break site of EML4‐ALK report and a rare PRKAR1A‐ALK report analyzed by different ALK detection platforms in non‐small cell lung cancer patients
por: Du, Xue, et al.
Publicado: (2021)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
por: Yang, Shuang, et al.
Publicado: (2023)

EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Jin, Guang, et al.
Publicado: (2012)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022)

EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
por: Matsuda, Hironari, et al.
Publicado: (2021)

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
por: Takahashi, Ken, et al.
Publicado: (2020)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2021)

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012)

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib
por: Shahab, Shubin W., et al.
Publicado: (2023)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2022)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
por: Wu, Xueqian, et al.
Publicado: (2020)

The Author Response: EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Park, Jae Yong
Publicado: (2012)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
por: Pirker, Robert, et al.
Publicado: (2019)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
por: Li, Huihui, et al.
Publicado: (2023)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
por: Han, Dan, et al.
Publicado: (2022)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a1e6i4u8nqhp5pr3pbviju7nko